Form 8-K MEDIFAST INC For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Medifast (MED) Defended at DA Davidson
November 7, 2018 9:53 AM ESTDA Davidson analyst Linda Bolton Weiser reiterated a Buy rating and $249 price target on Medifast (NYSE: MED) telling clients to buy on today's pull-back.
Weiser commented, "MED reported 3Q18 sales of $139M, above consensus of $125M and guidance of $120M-$125M. Revenue growth... More
